HPTN 083-01

HPTN 083-01 is a clinical trial examining whether injectable cabotegravir (CAB) for PrEP (pre-exposure prophylaxis) is a safe and acceptable method of HIV prevention for adolescents assigned male at birth. HPTN 083-01 is a sub-study of a larger clinical trial called HPTN 083. HPTN 083 examines whether injectable CAB works as PrEP, but in men and transgender women who have sex with men 18 years or older.

This study is a collaboration between the HIV Prevention Trials Network (HPTN), the Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN), and ViiV Healthcare.